SCHEMBL26444597

SCHEMBL26444597

CCOC(=O)/C=C/C(C)(C)C(F)(F)F

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HCAR2 Q8TDS4 2/20 0.48
MAPT P10636 5/20 0.41
CA12 O43570 1/20 0.39
CA1 P00915 1/20 0.39
CA2 P00918 1/20 0.39
CA7 P43166 1/20 0.39
CA9 Q16790 1/20 0.39
CA14 Q9ULX7 1/20 0.39
NPSR1 Q6W5P4 1/20 0.38
ALDH1A1 P00352 3/20 0.37
MLYCD O95822 1/20 0.36
TTR P02766 1/20 0.36
DPP4 P27487 1/20 0.36
ATM Q13315 1/20 0.35
LMNA P02545 2/20 0.34
MDM2 Q00987 1/20 0.34
CYP3A4 P08684 1/20 0.34
HSD17B10 Q99714 1/20 0.33
MAPK1 P28482 1/20 0.33
MAOB P27338 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27576206 1.00 HCAR2 (0.48) HCAR2MAPTCA12CA1CA2
SCHEMBL23666175 0.86 HCAR2 (0.54) HCAR2MAPTCA12CA1CA2
SCHEMBL17285584 0.84 HCAR2 (0.52) HCAR2MAPTCA12CA1CA2
SCHEMBL2969895 0.82 HCAR2 (0.50) HCAR2MAPTCA12CA1CA2
SCHEMBL2969893 0.82 HCAR2 (0.50) HCAR2MAPTCA12CA1CA2
SCHEMBL195983 0.82 HCAR2 (0.54) HCAR2MAPTCA12CA1CA2
SCHEMBL195984 0.82 HCAR2 (0.54) HCAR2MAPTCA12CA1CA2
SCHEMBL863510 0.82 HCAR2 (0.54) HCAR2MAPTCA12CA1CA2
SCHEMBL1879178 0.79 HCAR2 (0.56) HCAR2MAPTCA12CA1CA2
SCHEMBL3594049 0.79 HCAR2 (0.56) HCAR2MAPTCA12CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230128062-A1 AZABICYCLIC SUBSTITUTED OXASPIRO DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) 2023-04-27 US disclosed
US-20230128062-A1 AZABICYCLIC SUBSTITUTED OXASPIRO DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) 2023-04-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230128062-A1 AZABICYCLIC SUBSTITUTED OXASPIRO DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF CYP4A11, CYP51A1, CYP4F11 HCAR2 362/4885MAPT 4454/4885CA12 1318/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.